Shijiazhuang Yiling Pharmaceutical Past Earnings Performance
Past criteria checks 6/6
Shijiazhuang Yiling Pharmaceutical has been growing earnings at an average annual rate of 33.6%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 21.3% per year. Shijiazhuang Yiling Pharmaceutical's return on equity is 22.8%, and it has net margins of 20.6%.
Key information
33.6%
Earnings growth rate
33.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 21.3% |
| Return on equity | 22.8% |
| Net Margin | 20.6% |
| Next Earnings Update | 27 Apr 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shijiazhuang Yiling Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 13,162 | 2,706 | 3,890 | 1,074 |
| 30 Jun 23 | 13,757 | 2,919 | 3,998 | 1,061 |
| 31 Mar 23 | 13,746 | 3,080 | 3,917 | 1,039 |
| 31 Dec 22 | 12,533 | 2,362 | 3,888 | 1,032 |
| 30 Sep 22 | 9,951 | 1,535 | 3,348 | 806 |
| 30 Jun 22 | 9,787 | 1,428 | 3,410 | 807 |
| 31 Mar 22 | 9,170 | 1,153 | 3,538 | 763 |
| 01 Jan 22 | 10,117 | 1,344 | 3,968 | 792 |
| 30 Sep 21 | 10,447 | 1,426 | 4,218 | 802 |
| 30 Jun 21 | 10,192 | 1,469 | 4,058 | 760 |
| 31 Mar 21 | 10,117 | 1,455 | 3,886 | 731 |
| 31 Dec 20 | 8,782 | 1,219 | 3,441 | 654 |
| 30 Sep 20 | 7,925 | 1,048 | 3,048 | 518 |
| 30 Jun 20 | 7,328 | 866 | 2,973 | 468 |
| 31 Mar 20 | 6,609 | 756 | 2,862 | 437 |
| 31 Dec 19 | 5,825 | 607 | 2,584 | 391 |
| 30 Sep 19 | 5,336 | 612 | 2,375 | 399 |
| 30 Jun 19 | 5,098 | 606 | 2,260 | 371 |
| 31 Mar 19 | 4,784 | 577 | 2,033 | 338 |
| 01 Jan 19 | 4,815 | 599 | 2,116 | 317 |
| 30 Sep 18 | 4,848 | 653 | 2,160 | 260 |
| 30 Jun 18 | 4,537 | 649 | 1,911 | 340 |
| 31 Mar 18 | 4,347 | 632 | 1,917 | 262 |
| 31 Dec 17 | 4,081 | 541 | 1,876 | 217 |
| 30 Sep 17 | 3,972 | 555 | 1,794 | 138 |
| 30 Jun 17 | 4,036 | 569 | 1,948 | 0 |
| 31 Mar 17 | 4,050 | 570 | 1,955 | 0 |
| 31 Dec 16 | 3,850 | 533 | 1,861 | 0 |
| 30 Sep 16 | 3,665 | 527 | 1,760 | 0 |
| 30 Jun 16 | 3,538 | 510 | 1,672 | 0 |
| 31 Mar 16 | 3,439 | 489 | 1,600 | 0 |
| 31 Dec 15 | 3,185 | 430 | 1,464 | 0 |
| 30 Sep 15 | 3,161 | 395 | 1,460 | 0 |
| 30 Jun 15 | 3,089 | 376 | 1,444 | 0 |
| 31 Mar 15 | 2,980 | 377 | 1,396 | 0 |
| 31 Dec 14 | 2,921 | 354 | 1,409 | 0 |
| 30 Sep 14 | 2,877 | 312 | 1,503 | 0 |
| 30 Jun 14 | 2,871 | 294 | 1,525 | 0 |
| 31 Mar 14 | 2,711 | 275 | 1,462 | 0 |
| 31 Dec 13 | 2,490 | 244 | 1,388 | 0 |
| 30 Sep 13 | 2,416 | 248 | 1,355 | 0 |
| 30 Jun 13 | 2,102 | 196 | 1,238 | 0 |
Quality Earnings: 002603 has high quality earnings.
Growing Profit Margin: 002603's current net profit margins (20.6%) are higher than last year (15.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002603's earnings have grown significantly by 33.6% per year over the past 5 years.
Accelerating Growth: 002603's earnings growth over the past year (76.4%) exceeds its 5-year average (33.6% per year).
Earnings vs Industry: 002603 earnings growth over the past year (76.4%) exceeded the Pharmaceuticals industry 8.2%.
Return on Equity
High ROE: 002603's Return on Equity (22.8%) is considered high.